CoChat

3D organ-on-a-chip: The convergence of microphysiological systems and organoids

Open access
Baptista, Leandra S., Porrini, Constance, Kronemberger, Gabriela S., Kelly, Daniel J., Perrault, Cecile M. · 2022 · Frontiers in Cell and Developmental Biology

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Abstract

Medicine today faces the combined challenge of an increasing number of untreatable diseases and fewer drugs reaching the clinic. While pharmaceutical companies have increased the number of drugs in early development and entering phase I of clinical trials, fewer actually successfully pass phase III and launch into the market. In fact, only 1 out of every 9 drugs entering phase I will launch. In vitro preclinical tests are used to predict earlier and better the potential of new drugs and thus avoid expensive clinical trial phases. The most recent developments favor 3D cell culture and human stem cell biology. These 3D humanized models known as organoids better mimic the 3D tissue architecture and physiological cell behavior of healthy and disease models, but face critical issues in production such as small-scale batches, greater costs (when compared to monolayer cultures) and reproducibility. To become the gold standard and most relevant biological model for drug discovery and development, organoid technology needs to integrate biological culture processes with advanced microtechnologies, such as microphysiological systems based on microfluidics technology. Microphysiological systems, known as organ-on-a-chip, mimic physiological conditions better than conventional cell culture models since they can emulate perfusion, mechanical and other parameters crucial for tissue and organ physiology. In addition, they reduce labor cost and human error by supporting automated operation and reduce reagent use in miniaturized culture systems. There is thus a clear advantage in combining organoid culture with microsystems for drug development. The main objective of this review is to address the recent advances in organoids and microphysiological systems highlighting crucial technologies for reaching a synergistic strategy, including bioprinting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcell.2022.1043117

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Organoids culture. (A) Traditional organoid culture relies on several disadvantages that can be partially solved by culturing organoids in a microfluidic chip (B). The laminar flow of microfluidics provides a controlled dynamic environment increasing the reproducibility while reducing cost of organoid culture. The large scale can be reached by parallel microfluidic devices. (C) The cell suspension of iPS-derived hepatic progenitors cells were injected inside a microfluidic chip to form spheroids maturated into liver organoids. The maturation was followed by an increase on their average diameter during organoid culture. “Adapted with permission from Wang et al., 2020. Copyright 2020 American Chemical Society.” (D) Co-culture spheroids from human lung adenocarcinoma cells (A549) and endothelial cells (HUVECs) were transferred to a microfluidic device previously seeded with endothelial cells and lung fibroblasts embedded in a hydrogel. The tumor spheroids were capable of integration with the microvascular network and to drug response evaluated by Live and Dead assay. “Adapted with permission from Paek et al., 2019. Copyright 2019 American Chemical Society.” Both systems described the convergence of organoids and microfluidic, however, the increase of the complexity in (D) decreases its susceptibility to automation, large scale and reproducibility.
FIGURE 1 Organoids culture. (A) Traditional organoid culture relies on several disadvantages that can be partially solved by culturing organoids in a microfluidic chip (B). The laminar flow of microfluidics provides a controlled dynamic environment increasing the reproducibility while reducing cost of organoid culture. The large scale can be reached by parallel microfluidic devices. (C) The cell suspension of iPS-derived hepatic progenitors cells were injected inside a microfluidic chip to form spheroids maturated into liver organoids. The maturation was followed by an increase on their average diameter during organoid culture. “Adapted with permission from Wang et al., 2020. Copyright 2020 American Chemical Society.” (D) Co-culture spheroids from human lung adenocarcinoma cells (A549) and endothelial cells (HUVECs) were transferred to a microfluidic device previously seeded with endothelial cells and lung fibroblasts embedded in a hydrogel. The tumor spheroids were capable of integration with the microvascular network and to drug response evaluated by Live and Dead assay. “Adapted with permission from Paek et al., 2019. Copyright 2019 American Chemical Society.” Both systems described the convergence of organoids and microfluidic, however, the increase of the complexity in (D) decreases its susceptibility to automation, large scale and reproducibility.CC BY · PubMed Central
FIGURE 2 3D Bioprinting approaches can contribute to scalability of organoids-on-a-chip. (A) A cell suspension can be bioprinted inside a predesigned chip to form organoids or (B) organoids can be directly bioprinted inside a regular chip. In both scenarios the development of a specific composition of bioink according to the type of organoid is required. (C) The microfluidics chips can contain sensors, for example, to measure the real-time oxygen consumption from each organoid. Additional assays can be carried out inside the chip. The organoid culture supernatant can be harvested, and the levels of cytokines measured using multiplex assays. Optical transparent chips also allow fluorescent-based assays such as live and dead viability assay (D).
FIGURE 2 3D Bioprinting approaches can contribute to scalability of organoids-on-a-chip. (A) A cell suspension can be bioprinted inside a predesigned chip to form organoids or (B) organoids can be directly bioprinted inside a regular chip. In both scenarios the development of a specific composition of bioink according to the type of organoid is required. (C) The microfluidics chips can contain sensors, for example, to measure the real-time oxygen consumption from each organoid. Additional assays can be carried out inside the chip. The organoid culture supernatant can be harvested, and the levels of cytokines measured using multiplex assays. Optical transparent chips also allow fluorescent-based assays such as live and dead viability assay (D).CC BY · PubMed Central
FIGURE 3 Organoids-on-a-chip for drug development. (A) Human primary cells can be isolated from healthy and unhealthy tissue biopsies and expanded in numbers. The resulting cells can be used to form organoids (B). (C) Organoids can be embedded into hydrogels serving as a bioink for bioprinting protocols inside a chip. To provide scalability to the process, the resulting cells can be embedded into hydrogels serving as a bioink for bioprinting protocols to form organoids inside a chip (D). The convergence of organoids and microfluidic technologies is named in this review as organoids on a chip, serving as a complex 3D organ model for drug development (E).
FIGURE 3 Organoids-on-a-chip for drug development. (A) Human primary cells can be isolated from healthy and unhealthy tissue biopsies and expanded in numbers. The resulting cells can be used to form organoids (B). (C) Organoids can be embedded into hydrogels serving as a bioink for bioprinting protocols inside a chip. To provide scalability to the process, the resulting cells can be embedded into hydrogels serving as a bioink for bioprinting protocols to form organoids inside a chip (D). The convergence of organoids and microfluidic technologies is named in this review as organoids on a chip, serving as a complex 3D organ model for drug development (E).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 90

Metadata

Authors
Baptista, L. S., Porrini, C., Kronemberger, G. S., Kelly, D. J., & Perrault, C. M.
Affiliations
  • Universidade Federal do Rio de Janeiro (BR)
  • Trinity College Dublin (IE)
  • Royal College of Surgeons in Ireland (IE)
Corresponding author
Porrini, Constance
Venue
Frontiers in Cell and Developmental Biology
Published
2022-11-21
Volume
10
Pages
1043117-1043117
ISSN
2296-634X (ISSN-L)
OpenAlex
W4309740738
Cited by
90
References
106
Citations by year
2026: 22 · 2025: 31 · 2024: 22 · 2023: 15
FWCI
1.51
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Greater South Information System
Funders
H2020 Marie Skłodowska-Curie Actions
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
organ-on-a-chip, organoids, microphysiological systems, microfluidics, 3D cell culture, drug discovery, drug development, bioprinting, stem cell-derived models, reproducibility

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.